Literature DB >> 25407593

Medical management of invasive fungal infections of the central nervous system in pediatric cancer patients.

John H Carter1, Jennifer L Lenahan, Gisele E Ishak, J Russell Geyer, Jessica Pollard, Janet A Englund.   

Abstract

Fungal infections of the central nervous system (CNS) are associated with high mortality rates in immunocompromised patients. Surgical intervention is a mainstay of therapy, but not always possible. We describe the use of medical therapy for the treatment of CNS fungal infections in four pediatric cancer patients. Definitive resection was not performed in any patient. All patients initially received combination antifungal therapy with good clinical response; long-term survival was documented in two patients able to transition to long-term azole therapy. Prolonged antifungal therapy is an important option for treating invasive CNS fungal infections when surgery is not feasible.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  aspergillus; cancer; central nervous system; pediatric fungal infection; rhizopus

Mesh:

Substances:

Year:  2014        PMID: 25407593      PMCID: PMC4405402          DOI: 10.1002/pbc.25331

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  12 in total

1.  Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery.

Authors:  T Imai; T Yamamoto; S Tanaka; M Kashiwagi; S Chiba; H Matsumoto; T Uede
Journal:  Intern Med       Date:  1999-10       Impact factor: 1.271

Review 2.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.

Authors:  Rosalin M van Schie; Roger J M Brüggemann; Peter M Hoogerbrugge; D M W M te Loo
Journal:  J Antimicrob Chemother       Date:  2011-06-07       Impact factor: 5.790

5.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 6.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.

Authors:  Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach
Journal:  Pediatrics       Date:  2006-03-13       Impact factor: 7.124

Review 8.  Mucormycosis treated with posaconazole: review of 96 case reports.

Authors:  Joerg J Vehreschild; Andrea Birtel; Maria J G T Vehreschild; Blasius Liss; Fedja Farowski; Matthias Kochanek; Michal Sieniawski; Angela Steinbach; Kerstin Wahlers; Gerd Fätkenheuer; Oliver A Cornely
Journal:  Crit Rev Microbiol       Date:  2012-08-24       Impact factor: 7.624

Review 9.  Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.

Authors:  Vijayalakshmi Nagappan; Stan Deresinski
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

10.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.